Cervical cancer: prevention and screening (recent data)

To date, despite historical success in the prevention of cervical cancer (CC), yearly 530,000 new cases of the disease are diagnosed, and more than 270,000 women die from it. The advantage of cytological screening for carcinoma and precancerous lesions of the cervix has partially reached its peak due to its relatively low sensitivity - 58-80%. Since the vaccination against human papillomavirus (HPV) does not replace cervical cancer screening, in countries where it is introduced, it is necessary to develop and strengthen programs aimed at the prevention of infection caused by HPV, and also precancerous conditions and cancer of the cervix. These activities can be divided into primary (vaccination of girls aged 9-13 years), secondary (women over 30 years - screening and treatment, if necessary) and tertiary (all women, if necessary, - cervical cancer treatment at any age) prevention.